Date: November 11, 2026

Shareholders Agreement Details

Parties to Agreement:

  • Alivus Life Sciences Limited ("Company")
  • IQGEN-X Pharma Private Limited
  • Dr. Mandar Kodgule & Dr. Yogita Kodgule (collectively 'Continuing Existing Shareholders'/'CES')

Purpose of Agreement:

To record shareholders' mutual understanding with respect to inter se rights and obligations by virtue of their shareholding and certain other matters as mentioned in the Shareholders Agreement (SHA).

Existing Shareholding Structure:

The Company had previously entered into a share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited.

Significant Terms of Agreement:

  • The Company has an option to buy the remaining 24% of CES shareholding at the end of 5 years from the date of closing of this transaction at a pre-agreed Benchmark price defined in the SHA
  • Board Composition: 3 Directors (2 from the Company, 1 from CES)
  • No transfer of shares except as permitted by the Agreement

Governance and Control Impact:

  • No impact on management or control of the listed entity (Alivus Life Sciences Limited)
  • The Company has right to appoint majority Directors in IQGEN-X
  • No potential conflict of interest arising out of this SHA

Relationship Status:

  • The parties are not related to promoter/promoter group/group companies in any manner
  • The transaction does not fall within related party transactions
  • The Company has entered into share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited

Regulatory Compliance:

  • Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026
  • No restrictions or liabilities imposed upon the listed entity

Not Specified Sections

Financial Results, Dividend Declaration, KMP/Board/Auditor Changes, Board Meeting Outcomes, Auditor's Report, Disinvestment/Strategic Actions, Media Release/Investor Communication, Other Operational/Legal/Strategic Disclosures